

ESMO Breast Cancer Annual Meeting 2025
We’re thrilled to share that our poster titled “Large-scale validation of a robust artificial intelligence algorithm for detection of invasive breast cancer on H&E images” has been awarded Best Poster at this year’s ESMO Breast Cancer Annual Congress 2025.

The joint study with Emory University, University Clinic Erlangen and University of Regensburg shows that our AI software Mindpeak Breast H&E can reliably distinguish invasive breast cancer from non-invasive in-situ lesions and healthy tissue with outstanding accuracy.
On one of the most diverse datasets to date, including data from 59 institutions, the algorithm achieved a AUC of 0.997 demonstrating near-perfect classification performance.
Our results show that Mindpeak Breast H&E is ready to enable effective case prioritization for pathologists to achieve faster diagnosis and treatment for patients in need. This capability will help empower pathologists worldwide in maintaining high standards of patient care amid increasing case volumes.
Congratulations to the whole team and contributors: Patrick Frey, Andre Kochanke, PhD, Sunil Badve, Prof. Dr. med. Dr. rer. biol. hum. Ramona Erber, Niklas Abele, Diego Calvopina, PhD, Khalid Daifalla, Ralf Banisch, David Mulder, and Tobias Lang!
More News

A new strategic collaboration
A new strategic collaboration between life science clusters from Northern Europe and the UK’s National Institute for Health and Care Research (NIHR) is set to ...
Read more …
Pacira BioSciences Acquires GQ Bio
HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...
Read more …
CrystalsFirst Scales Operations...
CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...
Read more …